Drawing for DRH

USPTO serial 88729932

DRH

Reviewed by CopyMark Law Group

Reg. 6106256Status 700Renewal
Filing date
Status date
Registration date
Jul 21, 2020
Examiner
KELLEY, EVELYN
Law office
PETITIONS OFFICE

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with DRH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $850

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Dean W. Amburn

Dean W. Amburn Amburn Law PLLC4833 Waldon Woods Dr.Commerce Township, MI 48382UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001protein in raw material form for scientific and medical research; proteins for detecting antibodies other than for medical use; diagnostic preparations for scientific or research use; diagnostic reagents for scientific or research use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic useACTIVE—
005diagnostic agents for medical use, namely, tumor markers; diagnostic agents, preparations and substances for medical purposes; antigens for medical purposes; diagnostic reagents for medical use; diagnostic agents for pharmaceutical use; in-vivo diagnostic agent used for detection and monitoring of angiogenesis and anti-angiogenic therapy; diagnostic biomarker reagents for medical purposes; protein arrays for diagnosing cancerACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 21, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 21, 2021CORVREVIEW OF CORRESPONDENCE COMPLETE - CERTIFICATE OF REG MAILED—
Jan 16, 2021PCGRPETITION TO DIRECTOR GRANTED—
Jan 14, 2021APETASSIGNED TO PETITION STAFF—
Aug 17, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 17, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 17, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 17, 2020TPDRTEAS PETITION TO DIRECTOR RECEIVED—
Jul 21, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 5, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 5, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 15, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 2, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 31, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 31, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 26, 2020ALIEASSIGNED TO LIE—
Mar 19, 2020ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Mar 18, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Mar 18, 2020GNSLLETTER OF SUSPENSION E-MAILED—
Mar 18, 2020CNSLSUSPENSION LETTER WRITTEN—
Mar 18, 2020XAECEXAMINER'S AMENDMENT ENTERED—
Mar 18, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 18, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 18, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 16, 2020DOCKASSIGNED TO EXAMINER—
Dec 20, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 20, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance